Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Deok Gie | - |
dc.contributor.author | Lee, Juhan | - |
dc.contributor.author | Seo, Won Jun | - |
dc.contributor.author | Lee, Jae Geun | - |
dc.contributor.author | Kim, Beom Seok | - |
dc.contributor.author | Kim, Myoung Soo | - |
dc.contributor.author | Kim, Soon Il | - |
dc.contributor.author | Kim, Yu Seun | - |
dc.contributor.author | Huh, Kyu Ha | - |
dc.date.accessioned | 2021-08-31T23:33:03Z | - |
dc.date.available | 2021-08-31T23:33:03Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-11-11 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/61905 | - |
dc.description.abstract | Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-matched analysis to investigate the association between rituximab and posttransplant atherosclerotic cardiovascular disease (ASCVD). Among 1299 eligible patients, 239 given rituximab induction were matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD during 8 years of follow-up was significantly lower in rituximab-treated patients, compared with matched controls (3.7% vs. 11.2%; P = 0.012). However, all-cause mortality did not differ by group (2.9% vs. 4%; P = 0.943). In multivariable Cox analysis, rituximab proved independently protective of ASCVD (hazard ratio = 0.34, 95% confidence interval: 0.14-0.83). The lower risk of ASCVD seen with rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant dialysis, or older age (>50 years). Rituximab induction confers a lower risk of ASCVD during the posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk of ASCVD is heightened. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | RENAL-TRANSPLANTATION | - |
dc.subject | B-CELLS | - |
dc.subject | CARDIAC OUTCOMES | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | ABO | - |
dc.subject | RISK | - |
dc.subject | RECIPIENTS | - |
dc.subject | INFUSION | - |
dc.subject | LYMPHOCYTES | - |
dc.subject | FLUVASTATIN | - |
dc.title | Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Won Jun | - |
dc.identifier.doi | 10.1038/s41598-019-52942-8 | - |
dc.identifier.scopusid | 2-s2.0-85074841248 | - |
dc.identifier.wosid | 000495611100067 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.9 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | RENAL-TRANSPLANTATION | - |
dc.subject.keywordPlus | B-CELLS | - |
dc.subject.keywordPlus | CARDIAC OUTCOMES | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ABO | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | RECIPIENTS | - |
dc.subject.keywordPlus | INFUSION | - |
dc.subject.keywordPlus | LYMPHOCYTES | - |
dc.subject.keywordPlus | FLUVASTATIN | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.